<DOC>
	<DOCNO>NCT02371629</DOCNO>
	<brief_summary>This study post-authorization commitment European Medicines Agency ( EMA ) . The study serve determine whether treatment patient stable , symptomatic Chronic Obstructive Pulmonary Disease ( COPD ) investigational drug NVA237 efficient safe . The efficacy safety drug test twice daily dose daily dosing . The primary criterion ass efficacy trough FEV1 ( define mean evaluation 23 h 15 min 23 h 45 min post dose ) measurements patient treat 12 week NVA237 b.i.d versus receive NVA237 o.d.for 12 week .</brief_summary>
	<brief_title>A Study Efficacy Safety NVA237 Patients With Moderate Severe COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Written informed consent must obtain assessment perform Male female adult age ≥40 year Patients stable COPD accord current GOLD strategy ( GOLD 2014 ) Current exsmokers smoke history least 10 pack year exsmoker may define subject smoke ≥ 6 month screen mMRC grade least 2 Visit 101 Patients airflow limitation indicate postbronchodilator FEV1 ≥ 30 % &lt; 80 % predict normal , postbronchodilator FEV1/FVC &lt; 0.70 Visit 101 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test ; Women childbearing potential , defined woman physiologically capable become pregnant , unless use effective method contraception dose study treatment Patients Type I uncontrolled Type II diabetes ; Patients history long QT syndrome whose QTc measure runin ( Fridericia method ) prolong ( &gt; 450 m male &gt; 460 female ) confirm central assessor Patients require long term oxygen therapy prescribe &gt; 12 h per day ; Patients history asthma .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Anticholinergic</keyword>
	<keyword>Antimuscarinic</keyword>
	<keyword>Chronic Obstructive Airway Disease</keyword>
	<keyword>Chronic Obstructive Lung Disease</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>COPD</keyword>
	<keyword>LAMA</keyword>
	<keyword>Lung Disease</keyword>
	<keyword>Lung Diseases , Obstructive</keyword>
	<keyword>Lung Function</keyword>
	<keyword>Muscarinic receptor antagonist</keyword>
	<keyword>Pulmonary Disease , Chronic Obstructive</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
</DOC>